10th IRAINIAN JOINT Cardio Vascular Congress
10th IRAINIAN JOINT Cardio Vascular Congress Read More »
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to
Baseline cardiovascular risk assessment in cancer patients Read More »
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS are collectively improving the overall outcomes including survival and quality
5-FU based Chemotherapy and CV Toxicities | Radcliffe Cardiology Read More »
http://cardionco.com/wp-content/uploads/2025/01/IMG_3976.mp4 17 Y old young male with lymphoma Came by severe dyspnea Lymphoma with RA obstruction by extra-Cardiac mass and pericardial effusion
17 Y old young male with lymphoma Read More »
http://cardionco.com/wp-content/uploads/2025/01/IMG_1726.mp4 51-year-old female presented with dyspnea TTE: 32 × 31 mm Cystic Mass in Right Atrium adjacent to Tricuspid Valve Systolic PAP: 45 mmHg
“Cardiac Hydatid Cyst” (Echinococcus Cysts ) in Right Atrium Read More »
Abstract Purpose: Cardiotoxicity is one of the major concerns in breast cancer treatment, significantly affecting patient outcomes. To improve the likelihood of favorable outcomes for breast cancer survivors, it is essential to carefully balance the potential advantages of treatment methods with the risks of harm to healthy tissues, including the heart. There is currently a lack